MICROSOLV TECHNOLOGY CORPORATION
HPLC Columns and Chromatography Accessories

SINCE 1992

Ritonavir Analyzed with HPLC – AppNote

A Reproducible Method for Analysis of a Protease Inhibitor

Click *HERE* for Column Ordering Information.

A rapid, sensitive, and Reproducible Method has been developed for this Antiretroviral Medication. The data below, *(an overlay of 10 chromatograms)* illustrates how the compound can be adequately Retained and detected using this straightforward Method.

A Phenyl ring in the Column Stationary Phase provides strategic use of π-π Interaction with the Analyte making possible the use of a very simple, Mass Spec-friendly Mobile Phase with Formic Acid as an additive.

MICROSOLV TECHNOLOGY CORPORATION

HPLC Columns and Chromatography Accessories

SINCE 1992



10 Injections of Ritonavir

MICROSOLV TECHNOLOGY CORPORATION
HPLC Columns and Chromatography Accessories

SINCE 1992



Method Conditions

Column: Cogent Phenyl Hydride™, 4µm, 100Å
Catalog No.: 69020-10P
Dimensions: 4.6mm x 100mm
Mobile Phase: (65:35) Acetonitrile / DI Water with 0.1% Formic Acid
Injection vol.: 5µL
Flow rate: 1.0mL / minute
Detection: UV @ 254nm
Sample Preparation: Ritonavir standard prepared as 1.0mg / mL Standard Solution in Mobile Phase
t_0: 1.20 Minutes
K: 1.2

Notes: Ritonavir was initially developed as an independent Antiviral Agent but has been shown to possess advantageous properties in combination regimens with low-dose Ritonavir and other Protease Inhibitors. Currently, it is more commonly used as a booster of other Protease Inhibitors.

MICROSOLV TECHNOLOGY CORPORATION

HPLC Columns and Chromatography Accessories

SINCE 1992

COGENT HPLC Columns™